Pixantrone as bridging therapy to allogeneic transplantation or in chimeric antigen receptor T‐cell pathway in patients with diffuse large B‐cell lymphoma-Reference-Cited by-同舟云学术

Pixantrone as bridging therapy to allogeneic transplantation or in chimeric antigen receptor T‐cell pathway in patients with diffuse large B‐cell lymphoma

Published:2023-07-21 Issue:5 Volume:41 Page:947-950
ISSN:0278-0232
Container-title:Hematological Oncology
language:en
Short-container-title:Hematological Oncology

Author:

Lolli Ginevra¹²,Argnani Lisa²,Gini Guido³,Casadei Beatrice¹,Pellegrini Cinzia¹,Tani Monica⁴,Pavone Vincenzo⁵,Cimminiello Michele⁶,Bonifazi Francesca⁷,Zinzani Pier Luigi¹²^ORCID

Affiliation:

1. IRCCS Azienda Ospedaliero‐Universitaria di Bologna Istituto di Ematologia “Seràgnoli” Bologna Italy

2. Dipartimento di Scienze Mediche e Chirurgiche Università di Bologna Bologna Italy

3. Clinica di Ematologia AOU Ospedali Riuniti Ancona Italy

4. U.O.C Ematologia Ospedale Santa Maria delle Croci Ravenna Italy

5. Department of Hematology and Bone Marrow Transplant Hospital Card. G. Panico Tricase Italy

6. Dipartimento Oncologico U.O.C. di Ematologia‐Centro Trapianti di Cellule Staminali Azienda Ospedaliera Regionale “San Carlo” di Potenza Potenza Italy

7. IRCCS Azienda‐ospedaliero Universitaria di Bologna Bologna Italy

Publisher

Wiley

Subject

Cancer Research,Oncology,Hematology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/hon.3211

Reference10 articles.

1. The Novel Therapeutic Landscape for Relapsed/Refractory Diffuse Large B Cell Lymphoma

2. Cellular Immunotherapy for Refractory Diffuse Large B Cell Lymphoma in the Chimeric Antigen Receptor-Engineered T Cell Era: Still a Role for Allogeneic Transplantation?

3. Allogeneic transplantation provides durable remission in a subset of DLBCL patients relapsing after autologous transplantation